US 11,911,514 B2
Extended-release pharmaceutical composition containing lacosamide
Na Kyeom Lee, Anyang-si (KR); Jin Hyeong Park, Suwon-si (KR); and Mi Hong Min, Seongnam-si (KR)
Assigned to WHAN IN PHARMACEUTICAL COMPANY, Seoul (KR)
Appl. No. 16/969,610
Filed by WHAN IN Pharmaceutical Company, Seoul (KR)
PCT Filed Jan. 7, 2019, PCT No. PCT/KR2019/000219
§ 371(c)(1), (2) Date Aug. 13, 2020,
PCT Pub. No. WO2019/160243, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 10-2018-0018584 (KR), filed on Feb. 14, 2018.
Prior Publication US 2021/0023013 A1, Jan. 28, 2021
Int. Cl. A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/165 (2006.01); A61K 9/00 (2006.01)
CPC A61K 9/2866 (2013.01) [A61K 9/282 (2013.01); A61K 31/165 (2013.01); A61K 9/0053 (2013.01)] 7 Claims
 
1. A pharmaceutical composition comprising lacosamide or a salt thereof as an active ingredient,
the composition comprising an immediate release layer and an extended release layer,
wherein the extended release layer comprises cellulose derivative and wax or wax-like lipid in a weight ratio of 1:0.1 to 1:10,
wherein the pharmaceutical composition is administered orally once a day;
wherein the pharmaceutical composition is of a two-layered tablet dosage form;
wherein the cellulose derivative is at least one selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, methylcellulose and hydroxyethyl cellulose;
wherein the wax or wax-like lipid is at least one selected from the group consisting of glyceryl behenate, glyceryl palmitostearate and glyceryl stearate; and
wherein the active ingredient in the immediate release layer and the active ingredient in the extended release layer are in a weight ratio of 1:1 to 1:7.